Delenex Therapeutics Release: New Clinical Data On The Topical Application Of PENTRA®Bodies To Be Presented At The 44th Annual ESDR Meeting
9/2/2014 2:26:50 PM
Zurich, September 2, 2014 - Delenex Therapeutics AG, a clinical stage biopharmaceutical company primarily developing treatments for dermatologic diseases using its proprietary PENTRA®Bodies, today announced that Prof. Dr. Georg Stingl from the Medical University in Vienna, Austria will present a late-breaking poster on new clinical data of DLX105 at this year’s European Society for Dermatological Research Meeting in Copenhagen, Denmark. DLX105 is an anti-TNF? PENTRA®Body based on Delenex’ proprietary antibody platform that is applied topically to the skin of mild to moderate psoriasis patients.
The poster (LB011) “Topical administration of the single-chain anti-TNF? antibody DLX105 suppresses TNF? and Th17 cytokines in psoriatic skin“ will be presented on Thursday, September 11, 2014, at 6:30 PM in the late-breaking poster area at the Tivoli Congress Center in Copenhagen, Denmark.
Further information can be found on the ESDR 2014 website http://www.esdr2014.org/.
About Delenex Therapeutics AG
Delenex is a privately-held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex’ proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).
For further details please contact:
Jakob Schlapbach, CFO
Delenex Therapeutics AG
Help employers find you! Check out all the jobs and post your resume.
comments powered by